Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-11077.57%
operating margin TTM
-11002.14%
revenue TTM
484.48 Thousand
revenue per share TTM
0.03$
valuation ratios | |
|---|---|
| pe ratio | -7.27 |
| peg ratio | -1.40 |
| price to book ratio | 30.62 |
| price to sales ratio | 756.90 |
| enterprise value multiple | -8.40 |
| price fair value | 30.62 |
profitability ratios | |
|---|---|
| gross profit margin | -86.29% |
| operating profit margin | -11002.14% |
| pretax profit margin | -11077.43% |
| net profit margin | -11077.57% |
| return on assets | -87.39% |
| return on equity | -186.06% |
| return on capital employed | -108.86% |
liquidity ratios | |
|---|---|
| current ratio | 4.49 |
| quick ratio | 4.49 |
| cash ratio | 4.25 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 218.22 |
| days of payables outstanding | 947.91 |
| cash conversion cycle | -729.69 |
| receivables turnover | 1.67 |
| payables turnover | 0.39 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.04 |
| debt equity ratio | 0.19 |
| long term debt to capitalization | 0.11 |
| total debt to capitalization | 0.16 |
| interest coverage | -17.09 |
| cash flow to debt ratio | -20.52 |
cash flow ratios | |
|---|---|
| free cash flow per share | -9.27 |
| cash per share | 9.89 |
| operating cash flow per share | -9.26 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -20.52 |
| short term coverage ratios | -63.81 |
| capital expenditure coverage ratio | -3,050.89 |
Frequently Asked Questions
When was the last time Inhibrx Biosciences, Inc. (NASDAQ:INBX) reported earnings?
Inhibrx Biosciences, Inc. (INBX) published its most recent earnings results on 14-11-2025.
What is Inhibrx Biosciences, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Inhibrx Biosciences, Inc. (NASDAQ:INBX)'s trailing twelve months ROE is -186.06%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Inhibrx Biosciences, Inc. (INBX) currently has a ROA of -87.39%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did INBX's net profit margin stand at?
INBX reported a profit margin of -11077.57% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is INBX's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 4.49 in the most recent quarter. The quick ratio stood at 4.49, with a Debt/Eq ratio of 0.19.